Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 10Endocrine 10Thoracic 1Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Sarcoma 4Osteosarcoma 3Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Colorectal Neoplasms 1Carcinoid Tumor 1

Interventions

Quality of Life 2Fluorodeoxyglucose F18 2tivozanib 1tislelizumab 1surufatinib 1romidepsin 1repotrectinib 1olaparib 1lutetium Lu 177 dotatate 1fludarabine phosphate 1fludarabine 1entrectinib 1atezolizumab 1amino-acid, glucose, and electrolyte solution 1alectinib 1Surveys and Questionnaires 1Poly(ADP-ribose) Polymerase Inhibitors 1Patient Reported Outcome Measures 1PM 01183 1Nivolumab 1Molecular Diagnostic Techniques 1Magnetic Resonance Spectroscopy 1Lactones 1Irinotecan 1Interleukin-2 1Immunotherapy 1FAPI-46 1Drug Therapy 1Depsipeptides 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × surufatinib × Sarcoma × Clear all
NCT04579757 2025-05-08

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Hutchmed

Phase 1/2 Terminated
87 enrolled 29 charts
EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡